Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2018 · 10-Q
Revenue$8.12M$8.12M+33.5% vs Q3 2017 Net Income-$8.61M-$8.61MN/M vs Q3 2017 EPS Diluted-$0.16-$0.16N/M vs Q3 2017 Gross Profit$4,361,000+49.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,235,000N/M Free Cash Flowderived-$5,272,000N/M Margins · derivedGross margin53.7%+5.8 pt vs Q3 2017
Operating margin-105.9%−53.6 pt vs Q3 2017
Net margin-106.0%−141.1 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end